Abstract
The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER prospective cohort of frontline workers to study the relationship between antibody levels and protection against first-time post-vaccination infection and reinfection with SARS-CoV-2 from December 2021 to January 2023. All participants submitted weekly nasal swabs for rRT-PCR testing and blood samples quarterly and following infection or vaccination. Cases of first-time post-vaccination infection following a third dose of monovalent (origin strain WA-1) mRNA vaccine (n=613) and reinfection (n=350) were 1:1 matched to controls based on timing of blood draw and other potential confounders. Conditional logistic regression models were fit to estimate infection risk reductions associated with 3-fold increases in end titers for receptor binding domain (RBD). In first-time post-vaccination and reinfection study samples, most were female (67%, 57%), non-Hispanic (82%, 68%), and without chronic conditions (65%, 65%). The odds of first-time post-vaccination infection were reduced by 21% (aOR=0.79, 95% CI=[0.66-0.96]) for each 3-fold increase in RBD end titers. The odds of reinfection associated with a 3-fold increase in RBD end titers were reduced by 23% (aOR=0.77, 95% CI=[0.65-0.92] for unvaccinated individuals and 58% (aOR=0.42, 95% CI=0.22-0.84) for individuals with three mRNA vaccine doses following their first infection. Frontline workers with higher antibody levels following a third dose of mRNA COVID-19 vaccine were at reduced risk of SARS-CoV-2 during Omicron predominance. Among those with previous infections, the point estimates of risk reduction associated with antibody levels was greater for those with three vaccine doses compared to those who were unvaccinated.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: RS reports a relationship with American Council of Life Insurers that includes: speaking and lecture fees. RS reports a relationship with California legal case Ebers v. Castle Park that includes: consulting or advisory. RS reports a relationship with Geneticure, Inc. that includes: equity or stocks. RS reports a relationship with Beckman Coulter that includes: speaking and lecture fees. RS reports a relationship with Shay Emma Hammer Research Foundation that includes: board membership. RS has patent issued to Arizona Board of Regents on Behalf of the University of Arizona. MG reports a relationship with Infectious Diseases and Immunization Committee, Texas Pediatric Society, Texas Chapter of the American Academy of Pediatrics that includes: board membership.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol and procedures were reviewed and approved by the Arizona Department of Health, the University of Arizona Institutional Review Boards (IRBs), Baylor Scott and White Research Institute IRB, Kaiser Permanente Northwest IRB (IRB of record for the CDC and Abt Associates), St. Luke’s Hospital Duluth IRB, University of Miami Human Subjects Research Office, and University of Utah IRB. All study participants provided informed written consent for all study activities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data used in this analysis are currently unavailable to the public. Researchers who meet the criteria for access to confidential data need necessary approval from the relevant Institutional Review Boards to access the data.
